What is the mechanism by which allopurinol helps prevent uric acid buildup in tumor lysis syndrome?

Prepare for the Hematologic, Immunologic, and Neoplastic Disorders Test. Study with flashcards and multiple-choice questions, each with explanations and hints. Get ready for your exam!

Multiple Choice

What is the mechanism by which allopurinol helps prevent uric acid buildup in tumor lysis syndrome?

Explanation:
Allopurinol works by inhibiting xanthine oxidase, the enzyme that converts hypoxanthine and xanthine into uric acid during purine breakdown. In tumor lysis syndrome, a rapid surge of nucleic acids from dying tumor cells increases purine catabolism, raising uric acid levels and risking uric acid–related kidney injury. By blocking xanthine oxidase, allopurinol lowers the amount of uric acid produced, helping prevent its buildup. It does not directly convert uric acid to allantoin (that role belongs to uricase enzymes like rasburicase, which humans lack), and it does not by itself cure TLS or alter phosphate excretion.

Allopurinol works by inhibiting xanthine oxidase, the enzyme that converts hypoxanthine and xanthine into uric acid during purine breakdown. In tumor lysis syndrome, a rapid surge of nucleic acids from dying tumor cells increases purine catabolism, raising uric acid levels and risking uric acid–related kidney injury. By blocking xanthine oxidase, allopurinol lowers the amount of uric acid produced, helping prevent its buildup. It does not directly convert uric acid to allantoin (that role belongs to uricase enzymes like rasburicase, which humans lack), and it does not by itself cure TLS or alter phosphate excretion.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy